-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Bionomics' (BNOX) "In-Line" Rating Reaffirmed at Evercore ISI
Bionomics' (BNOX) "In-Line" Rating Reaffirmed at Evercore ISI
Bionomics (NASDAQ:BNOX – Get Rating)'s stock had its "in-line" rating reaffirmed by Evercore ISI in a note issued to investors on Tuesday, Benzinga reports. They currently have a $6.00 price target on the stock, down from their previous price target of $17.00. Evercore ISI's price target would suggest a potential upside of 20.24% from the stock's previous close.
Several other research analysts also recently commented on the stock. HC Wainwright downgraded shares of Bionomics from a "buy" rating to a "neutral" rating in a research note on Monday. Loop Capital began coverage on shares of Bionomics in a report on Tuesday, November 1st. They issued a "buy" rating and a $23.00 price target on the stock. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company's stock. Based on data from MarketBeat, Bionomics presently has a consensus rating of "Moderate Buy" and a consensus price target of $16.67.
Get Bionomics alerts:Bionomics Price Performance
BNOX stock traded down $0.90 during trading on Tuesday, hitting $4.99. 1 shares of the company's stock traded hands, compared to its average volume of 5,746. Bionomics has a 52 week low of $5.30 and a 52 week high of $13.76. The business has a fifty day simple moving average of $7.67 and a 200 day simple moving average of $7.39.
Bionomics Company Profile
(Get Rating)Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder.
See Also
- Get a free copy of the StockNews.com research report on Bionomics (BNOX)
- General Mills Retreats To More Attractive Territory
- Will Tesla Shares Rally If Musk Steps Down From Twitter?
- Can Chewy Fetch Double Digit Gains in 2023?
- 5 Down But Not Out Stocks To Watch For 2023
- Eli Lilly Expects Enduring Growth, Despite Immediate Challenges
Receive News & Ratings for Bionomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bionomics and related companies with MarketBeat.com's FREE daily email newsletter.
Bionomics (NASDAQ:BNOX – Get Rating)'s stock had its "in-line" rating reaffirmed by Evercore ISI in a note issued to investors on Tuesday, Benzinga reports. They currently have a $6.00 price target on the stock, down from their previous price target of $17.00. Evercore ISI's price target would suggest a potential upside of 20.24% from the stock's previous close.
生物學 (納斯達克:BNOX — 獲得評分)本辛加報導,股票有其「在線」評級由 Evercore ISI 在週二發給投資者的紙條中重申。他們目前的股票價格目標為 6.00 美元,低於之前的價格目標 17.00 美元。永可 ISI 的價格目標將表明該股票的前一收盤價有 20.24% 的潛在上漲空間。
Several other research analysts also recently commented on the stock. HC Wainwright downgraded shares of Bionomics from a "buy" rating to a "neutral" rating in a research note on Monday. Loop Capital began coverage on shares of Bionomics in a report on Tuesday, November 1st. They issued a "buy" rating and a $23.00 price target on the stock. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company's stock. Based on data from MarketBeat, Bionomics presently has a consensus rating of "Moderate Buy" and a consensus price target of $16.67.
其他幾位研究分析師最近還評論了該股票。在周一的研究報告中,HC Wainwright 將生物學的股票從「買入」評級降至「中性」評級。環資本開始覆蓋生物學的股份在星期二, 11 月 1 日 (星期二).他們發布了「買入」評級和 23.00 美元的股票價格目標。兩位分析師對該股票進行了保持評級,其中四名分析師對該公司的股票進行了買入評級。根據 MarketBeat 的數據,生物學目前的共識評級為「中等買入」,共識價格目標為 16.67 美元。
Bionomics Price Performance
生物學價格性能
BNOX stock traded down $0.90 during trading on Tuesday, hitting $4.99. 1 shares of the company's stock traded hands, compared to its average volume of 5,746. Bionomics has a 52 week low of $5.30 and a 52 week high of $13.76. The business has a fifty day simple moving average of $7.67 and a 200 day simple moving average of $7.39.
BNOX 股票周二交易期間下跌 0.90 美元,觸及 4.99 美元。該公司股票的 1 股交易手,相比其平均交易量為 5,746。生物學具有 52 周低點為 5.30 美元,52 周高點為 13.76 美元。該業務有五十天的簡單移動平均線 7.67 美元和 200 天的簡單移動平均線 7.39 美元。
Bionomics Company Profile
生物學公司簡介
Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder.
Biomics Limited 是一家臨床階段生物製藥公司,發現並開發用於治療中樞神經系統疾病和癌症的新型候選藥物。公司的主要候選藥物包括 BNC210,一種 a7 菸鹼乙酰膽鹼受體的陰性同種異體調節劑,該藥物正處於治療社交焦慮症的 2 期臨床試驗中,以及用於治療創傷後應激障礙的 2b 期臨床試驗。
See Also
另請參閱
- Get a free copy of the StockNews.com research report on Bionomics (BNOX)
- General Mills Retreats To More Attractive Territory
- Will Tesla Shares Rally If Musk Steps Down From Twitter?
- Can Chewy Fetch Double Digit Gains in 2023?
- 5 Down But Not Out Stocks To Watch For 2023
- Eli Lilly Expects Enduring Growth, Despite Immediate Challenges
- 獲取有關生物學(BNOX)的研究報告的免費副本
- 通用米爾斯撤退到更具吸引力的領土
- 如果馬斯克從推特下台,特斯拉會分享反彈嗎?
- 耐嚼可以在 2023 年獲得雙位數的收益嗎?
- 5 年要關注的 2023 年股票下跌但未熄滅
- 儘管面臨面臨挑戰,但 Eli Lilly 預計持續增長
Receive News & Ratings for Bionomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bionomics and related companies with MarketBeat.com's FREE daily email newsletter.
每日接收生物學的新聞和評分 -在下面輸入您的電子郵件地址,以通過 MarketBeat.com 的免費每日電子郵件時事通訊接收生物學和相關公司的最新新聞和分析師評級的簡要每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧